28 febrero 2007
26 febrero 2007
22 febrero 2007
20 febrero 2007
19 febrero 2007
Genomica SAU ( Grupo Zeltia ) Patenta su Kit de identificación del HPV .
IN VITRO DIAGNOSTIC KIT FOR IDENTIFICATION OF HUMAN PAPILLOMAVIRUS IN CLINICAL SAMPLES
Publication number: WO2007017699
Publication date: 2007-02-15
Inventor: ESCOBAR IRENE GASCON (ES); MARIA LUISA VILLAHERMOSA JAEN (ES)
Applicant: GENOMICA S A U (ES); WILLIAMS GARETH OWEN (GB); ESCOBAR IRENE GASCON (ES); MARIA LUISA VILLAHERMOSA JAEN (ES)
Classification: - international: C12Q1/70; C12Q1/70; - European: Application number: WO2006GB50231 20060804 Priority number(s): GB20050016145 20050805
Abstract of WO2007017699
A method and kit for detection and typing of HPV in a sample are described, as is a reaction vessel for use in the method. Universal HPV primers are used to amplify a sample by PCR; the amplified sample is then hybridised to an array of HPV type-specific probes to determine the HPV type .
Publication number: WO2007017699
Publication date: 2007-02-15
Inventor: ESCOBAR IRENE GASCON (ES); MARIA LUISA VILLAHERMOSA JAEN (ES)
Applicant: GENOMICA S A U (ES); WILLIAMS GARETH OWEN (GB); ESCOBAR IRENE GASCON (ES); MARIA LUISA VILLAHERMOSA JAEN (ES)
Classification: - international: C12Q1/70; C12Q1/70; - European: Application number: WO2006GB50231 20060804 Priority number(s): GB20050016145 20050805
Abstract of WO2007017699
A method and kit for detection and typing of HPV in a sample are described, as is a reaction vessel for use in the method. Universal HPV primers are used to amplify a sample by PCR; the amplified sample is then hybridised to an array of HPV type-specific probes to determine the HPV type .
Yondelis de nuevo autorizado por Sanidad Francesa para ensayos clinicos
[RTF]
Spécialités pour lesquelles des ATU nominatives ont été octroyées ...
Formato de archivo: Rich Text Format - Spécialités pour lesquelles des ATU nominatives ont été octroyées en janvier 2007. Domaine thérapeutique, Spécialité (nom, dosage, forme pharmaceutique) ...afssaps.sante.fr/htm/5/atu/atu_nominati_janvier_2007.rtf
Spécialités pour lesquelles des ATU nominatives ont été octroyées ...
Formato de archivo: Rich Text Format - Spécialités pour lesquelles des ATU nominatives ont été octroyées en janvier 2007. Domaine thérapeutique, Spécialité (nom, dosage, forme pharmaceutique) ...afssaps.sante.fr/htm/5/atu/atu_nominati_janvier_2007.rtf
18 febrero 2007
16 febrero 2007
14 febrero 2007
13 febrero 2007
12 febrero 2007
11 febrero 2007
10 febrero 2007
09 febrero 2007
06 febrero 2007
Cáncer ,“el concepto de curación es muy abstracto”. “Cuando dentro de unas décadas se analicen nuestros métodos seguramente pensarán que son inhumano
Josep Baselga , ganador del "PREMIO INICIATIVA BMW 2007” .
05 febrero 2007
Synthesis of IB-01211, a Cyclic Peptide Containing 2,4-Concatenated Thia- and Oxazoles, via Hantzsch Macrocyclization.
2007 Feb 1 .
Synthesis of IB-01211, a Cyclic Peptide Containing 2,4-Concatenated Thia- and Oxazoles, via Hantzsch Macrocyclization.
Hernandez D, Vilar G, Riego E, Canedo LM, Cuevas C, Albericio F, Alvarez M.
Barcelona Science Park Josep Samitier 1-5, E-08028 Barcelona, Spain.
An efficient and versatile convergent synthesis of IB-01211 based on a combination of peptide and heterocyclic chemistry is described. The key step in the synthesis is macrocyclization through intramolecular Hantzsch formation of the thiazole ring. Dehydration of a free primary alcohol to furnish the exocyclic methylidene present in the natural product was applied during the macrocyclization.
Synthesis of IB-01211, a Cyclic Peptide Containing 2,4-Concatenated Thia- and Oxazoles, via Hantzsch Macrocyclization.
Hernandez D, Vilar G, Riego E, Canedo LM, Cuevas C, Albericio F, Alvarez M.
Barcelona Science Park Josep Samitier 1-5, E-08028 Barcelona, Spain.
An efficient and versatile convergent synthesis of IB-01211 based on a combination of peptide and heterocyclic chemistry is described. The key step in the synthesis is macrocyclization through intramolecular Hantzsch formation of the thiazole ring. Dehydration of a free primary alcohol to furnish the exocyclic methylidene present in the natural product was applied during the macrocyclization.
Aplidin Small cell lung cancer and targeted therapies.
2007 Mar 19
Small cell lung cancer and targeted therapies.
Blackhall FH , Shepherd FA
aChristie Hospital NHS Trust, Manchester, UK bPrincess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada.
PURPOSE OF REVIEW: Small cell lung cancer is a chemosensitive malignancy, yet long-term survival remains elusive for the majority of patients. Here, we report on progress in evaluating novel targeted therapies for the treatment of this disease. RECENT FINDINGS: Interferons, matrix metalloproteinase inhibitors, thalidomide, bevacizumab, ZD6474, imatinib, gefitinib, oblimersen and aplidine have all entered clinical trial in patients with small cell lung cancer. Immunotherapy approaches targeting cell surface antigens such as CD-56 (BB10901) and GD3 ganglioside are also being evaluated. Interferons, matrix metalloproteinase inhibitors, imatinib and gefitinib have failed to demonstrate efficacy for this disease. Preliminary data for thalidomide are promising and so results from trials of other antiangiogenics such as bevacizumab and ZD6474 are awaited with interest. SUMMARY: Although the promise of targeted therapy has yet to be realized in patients with small cell lung cancer, the number of agents available for evaluation provides new optimism that progress will be made over the next decades.
Small cell lung cancer and targeted therapies.
Blackhall FH , Shepherd FA
aChristie Hospital NHS Trust, Manchester, UK bPrincess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada.
PURPOSE OF REVIEW: Small cell lung cancer is a chemosensitive malignancy, yet long-term survival remains elusive for the majority of patients. Here, we report on progress in evaluating novel targeted therapies for the treatment of this disease. RECENT FINDINGS: Interferons, matrix metalloproteinase inhibitors, thalidomide, bevacizumab, ZD6474, imatinib, gefitinib, oblimersen and aplidine have all entered clinical trial in patients with small cell lung cancer. Immunotherapy approaches targeting cell surface antigens such as CD-56 (BB10901) and GD3 ganglioside are also being evaluated. Interferons, matrix metalloproteinase inhibitors, imatinib and gefitinib have failed to demonstrate efficacy for this disease. Preliminary data for thalidomide are promising and so results from trials of other antiangiogenics such as bevacizumab and ZD6474 are awaited with interest. SUMMARY: Although the promise of targeted therapy has yet to be realized in patients with small cell lung cancer, the number of agents available for evaluation provides new optimism that progress will be made over the next decades.
